Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BMEA |
---|---|---|
09:32 ET | 11984 | 5.49 |
09:34 ET | 631 | 5.48 |
09:36 ET | 2078 | 5.52 |
09:38 ET | 900 | 5.48 |
09:39 ET | 2507 | 5.48 |
09:41 ET | 3029 | 5.46 |
09:43 ET | 1191 | 5.48 |
09:45 ET | 3276 | 5.53 |
09:48 ET | 3463 | 5.53 |
09:50 ET | 2000 | 5.476 |
09:52 ET | 2078 | 5.5191 |
09:54 ET | 2108 | 5.51 |
09:56 ET | 1954 | 5.53 |
09:57 ET | 4054 | 5.57 |
09:59 ET | 1129 | 5.545 |
10:01 ET | 100 | 5.545 |
10:03 ET | 1000 | 5.53 |
10:06 ET | 1438 | 5.48 |
10:08 ET | 1692 | 5.45 |
10:10 ET | 2370 | 5.385 |
10:12 ET | 3613 | 5.37 |
10:14 ET | 4287 | 5.41 |
10:15 ET | 1152 | 5.39 |
10:17 ET | 1966 | 5.38 |
10:19 ET | 6324 | 5.35 |
10:21 ET | 2500 | 5.365 |
10:24 ET | 700 | 5.33 |
10:26 ET | 700 | 5.33 |
10:28 ET | 1155 | 5.36 |
10:30 ET | 7780 | 5.34 |
10:32 ET | 200 | 5.37 |
10:33 ET | 13353 | 5.355 |
10:35 ET | 2400 | 5.38 |
10:37 ET | 1700 | 5.41 |
10:39 ET | 7232 | 5.4 |
10:42 ET | 2990 | 5.39 |
10:44 ET | 849 | 5.39 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Biomea Fusion Inc | 192.7M | -1.5x | --- |
XBiotech Inc | 191.6M | -6.4x | --- |
Pyxis Oncology Inc | 188.4M | -2.4x | --- |
Candel Therapeutics Inc | 197.0M | -5.6x | --- |
Outlook Therapeutics Inc | 197.8M | -0.8x | --- |
INmune Bio Inc | 188.5M | -5.1x | --- |
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $192.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.57 |
Book Value | $4.72 |
P/E Ratio | -1.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.